Treatment for Cryptococcosis Gets FDA’s Orphan Drug Designation
The FDA has granted Orphan Drug designation to APX001 (Amplyx Pharmaceuticals) for the treatment of cryptococcosis.
Mycoses
Mycoses
Latest News
Voriconazole-Resistant Invasive Aspergillosis Associated With Higher Mortality
Patients with voriconazole-resistant invasive aspergillosis have a higher mortality rate compared with patients with voriconazole-susceptible infection.
Isavuconazole Not Noninferior to Caspofungin for Invasive Candida Infections
Isavuconazole did not demonstrate noninferiority compared with caspofungin in the primary treatment of proven candidemia or invasive candidiasis.
Identification and Control of Candida Auris Outbreak in a Hospital ICU
A recent outbreak of Candida auris in an ICU of the Oxford University Hospitals was determined to be primarily linked to reusable temperature probes.
Many Linens Delivered To US Hospitals Contaminated With Mucorales Mold
A recent microbiological surveillance study found that >10% of linens tested positive for the fungi Mucorales at 20% of the hospitals included in the study.
Rezafungin Gets Fast Track, QIDP Status for Prevention of Invasive Fungal Infections
The Phase 3 ReSPECT prophylaxis trial of rezafungin in patients undergoing allogeneic bone marrow transplantation is anticipated to start in the first quarter of 2019.
Coccidioidomycosis Screening Benefits TNFi Therapy Recipients
Screening of asymptomatic coccidioidomycosis within a Coccidioides-endemic area allowed for identifying and managing asymptomatic cases before patients began tumor necrosis factor-α inhibitor therapy.
Novel Nanodiagnostic Panel May Reduce Empiric Antifungal Use in High-Risk Candidemia
A novel nanodiagnostic panel may be helpful in reducing the length of empiric antifungal treatment in patients with multiple risk factors for candidemia.
Antifungal Use During Pregnancy and Risk of Stillbirth: What’s the Link?
Based on the findings, it was concluded that fluconazole use during pregnancy was not associated with significantly increased risks of stillbirth or neonatal death. However, the authors cautioned that the confidence intervals were wide and neither result was statistically significant.
Costs and Outcomes Associated With Invasive Aspergillosis Infections
Although rare even in high-risk groups, invasive aspergillosis is associated with high hospital mortality rates, excess duration of hospitalization, and a 40% relative increase in the odds of 30-day readmission.
Study Supports Development of a Vaccine for Recurrent Vulvovaginal Candidiasis
Results support further development of NDV-3A vaccine and provide guidance for meaningful clinical endpoints for immunotherapeutic management of recurrent vulvovaginal candidiasis.
Risk for Breakthrough Invasive Fungal Infections With Isavuconazole: More Data Needed
While isavuconazole is an important therapeutic option in the management of invasive fungal infections, the epidemiology and microbiology of breakthrough infections on this agent are not well understood.
First-in-Class Antifungal Fast-Tracked for Vulvovaginal Candidiasis
SCY-078 is an investigational antifungal agent that is a semi-synthetic derivative of the natural product enfumafungin.
First Test to Identify Candida auris Gets FDA Approval
The Bruker Maldi system is already cleared for use in identifying 333 species or species groups, including 424 bacteria and yeast species.
Antifungal Combination Treatment for Cryptococcal Meningitis in HIV
The absence of availability of amphotericin B or in conditions in which amphotericin B cannot be administered safely, the oral combination of fluconazole plus flucytosine provides an effective and sustainable alternative.
T2Candida May Shorten Time to Candida Detection, Species Identification
Researchers validated the clinical sensitivity of the T2Candida panel for the diagnosis of bloodstream infections caused by the 5 most common pathogenic Candida species.
Possible Microbial Contamination Prompts Voluntary Recall of Diabetes Drug
FDA posts a notification for a voluntarily recall of a diabetes drug over microbial contamination.
Long-Term Outcomes Following Prosthetic Valve Endocarditis Caused by Candida
Six-month survival was better in patients who received liposomal amphotericin B-based monotherapy than in those receiving a candin-based monotherapy.
Novel Antifungal Agent for Treatment of Aspergillus flavus Infections
F901318 has potent in vitro activity against A flavus and is highly active in both in vitro and in vivo models mimicking invasive human disease.
Fungal Infection-Free Survival Not Improved with Empirical Micafungin Treatment
Treatment was tested in critically ill patients with ICU-acquired sepsis, multiple Candida colonization, and multiple organ failure.
Want to read more?
Please login or register first to view this content.
Next post in Mycoses
